✦ LIBER ✦

Combination chemotherapy with mitomycin C and vindesine in the treatment of non small cell lung carcinoma (NSCLC)

Book ID: 121990737
Publisher: Elsevier Science
Year: 1986
Tongue: English
Weight: 166 KB
Volume: 2
Category: Article
ISSN: 0169-5002
DOI: 10.1016/S0169-5002(86)80478-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Karnofsky-adapted chemotherapy of non sm

Karnofsky-adapted chemotherapy of non small cell lung cancer (NSCLC) with ifosfamide/mitomycin C/vindesine

✍ M. Schroeder; H. A. Vaupel; L. Leimer; A. Brunöhler; M. Westerhausen 📂 Article 📅 1986 🏛 Springer-Verlag 🌐 English ⚖ 131 KB

Combination chemotherapy with mitomycin-

Combination chemotherapy with mitomycin-C, ifosfamide and vindesine in the treatment of NSCLC

✍ U. Gatzemeier; D. K. Hossfeld; H. Magnussen; D. Radenbach; R. Zschaber 📂 Article 📅 1986 🏛 Springer-Verlag 🌐 English ⚖ 134 KB

Combination chemotherapy with cisplatin,

Combination chemotherapy with cisplatin, vindesine and mitomycin-C for advanced, inoperable non-small-cell lung cancer

📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 142 KB

Combination chemotherapy of non-small ce

Combination chemotherapy of non-small cell lung cancer with mitomycin (MMC), vindesine (VDS) and cisplatin (DDP)

📂 Article 📅 1986 🏛 Elsevier Science 🌐 English ⚖ 99 KB

Combination chemotherapy with mitomycin,

Combination chemotherapy with mitomycin, vinblastine and cisplatinum for advanced non small cell lung cancer (NSCLC)

✍ Gaafar, R.M.; Hamza, M.R.; Zikri, Z.K.; El-Attar, I.; Abdel-Moneim, D.; Khaled, 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 144 KB

Combination chemotherapy with mitomycin-

Combination chemotherapy with mitomycin-C, cisplatin, and vinblastine in the treatment of non-small-cell lung cancer

✍ Niell, Harvey B. ;Griffin, John P. 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 443 KB

The drug combination of mitomycin-C, cisplatin, and vinblastine was administered to 30 patients with stage III non-small-cell lung cancer. All patients had a performance status of 50% or greater, had evaluable disease, and had not received previous chemotherapy. The overall response rate was 37% wit